X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Large Pharmaceutical Company in China Selects TrialMaster® EDC and Acuity Analytics for Major Clinical Study

Content Team by Content Team
16th August 2018
in Clinical Trials, Press Statements
Large Pharmaceutical Company in China Selects TrialMaster® EDC and Acuity Analytics for Major Clinical Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In a milestone transaction, a major pharmaceutical company based in China will undertake a multisite clinical study using TrialMaster EDC Suite and Acuity Analytics, from OmniComm Systems, Inc., , a leading global provider of clinical data management technology.

With eClinical solutions from OmniComm and related services, the pharmaceutical company will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial of a treatment for a well-known cognitive disorder. The trial represents the sponsor’s first use of TrialMaster and Acuity for a study. TrialMaster is the mobile-friendly, easy-to-use electronic data capture solution for Phase I – IV clinical trials. Acuity Analytics provides data aggregation, analytics and visualization tools.

OmniComm was selected based on TrialMaster’s inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process. Additionally, the pharmaceutical company selected Acuity because the product provides data visualization to manage the study and data analytics to make faster decisions.

“Building upon our significant traction in early phase trials, this award represents a major milestone for OmniComm, with a second sponsor in China this year now choosing to move to TrialMaster,” said Kuno van der Post, Ph.D., chief commercial officer from OmniComm. “Moreover, we are pleased with the selection of the Acuity data visualization tool, which is integrated with TrialMaster and can also support local languages.”

About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 6,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. Please visit www.omnicomm.com

Previous Post

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza

Next Post

Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
Breast Cancer Therapy
Clinical Trials

US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

27th September 2025
Sensor Technology
Clinical Trials

Enhancing Clinical Research with Advanced Sensor Technology

11th September 2025
Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Next Post

Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In